AstraZeneca expands access to Imfinzi in the UK

London-listed AstraZeneca (LSE: AZN) has received a positive reimbursement decision from the UK’s health technology assessor, for the immuno-oncology product Imfinzi (durvalumab).

The decision means the therapy is now available as an option for people with stage 3 unresectable non-small cell lung cancer (NSCLC), via a dedicated fund for oncology treatments, the Cancer Drugs Fund (CDF).

Funding through the CDF is subject to eligibility criteria being met. The therapy is not routinely funded through the country’s national healthcare provider for this indication.